NDAORALTABLETPriority Review
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
9
Clinical Trials (5)
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
Started May 2026
20 enrolled
BlinatumomabRevumenibLymphoblastic Leukemia+1 more
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Started Nov 2025
468 enrolled
Acute Myeloid Leukemias
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Started Mar 2025
415 enrolled
Acute Myeloid Leukemia, Adult
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Started Sep 2024
8 enrolled
Acute Myeloid Leukemia
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
Started Apr 2023
42 enrolled
Colorectal CancerSolid Tumors
Loss of Exclusivity
LOE Date
Jun 8, 2037
137 months away
Patent Expiry
Jun 8, 2037
Exclusivity Expiry
Nov 15, 2031